Azelastine HCl: A Review of the Old and New Formulations | Zendy

Jonathan M. Horbal | Zendy; Jonathan A. Bernstein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Azelastine HCl: A Review of the Old and New Formulations

Author(s) -

Jonathan M. Horbal,

Jonathan A. Bernstein

Publication year - 2010

Publication title -

clinical medicine insights therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.205

H-Index - 9

ISSN - 1179-559X

DOI - 10.4137/cmt.s3865

Subject(s) - azelastine , medicine , antihistamine , cetirizine , dermatology , histamine h1 receptor , pharmacodynamics , terfenadine , pharmacology , pharmacokinetics , antagonist , receptor

Azelastine HCl (Astelin™) is an intranasal antihistamine indicated for use in patients with seasonal allergic rhinitis (SAR) and non-allergic vasomotor rhinitis (VMR). A side effect of this medication is bitter taste which many patients find aversive. To address the issue of bitter taste, azelastine has been reformulated to include sucralose and sorbitol. The new formulation (Astepro™ 0.1%) is approved for seasonal and perennial allergic rhinitis and has been demonstrated to have comparable pharmacokinetics, pharmacodynamics and therapeutic efficacy compared to Astelin. More recently, Astepro at a concentration 0.15% has been approved for once a day use. This review will provide an overview of the old and new formulations of Azelastine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research